Ocular Therapeutix (OCUL) Receives Another Recommendation From Wall Street

September 8, 2018 - By Mary Kidd

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Logo

How Piper Jaffray Currently Rates Ocular Therapeutix (OCUL)

Analysts at Piper Jaffray has initiated coverage on Ocular Therapeutix (OCUL) with “Overweight” rating. This was sent to investors in a report on 7 September.

The stock increased 4.48% or $0.3 during the last trading session, reaching $6.99. About 486,320 shares traded or 16.49% up from the average. Ocular Therapeutix, Inc. (OCUL) has declined 34.95% since September 8, 2017 and is downtrending. It has underperformed by 47.52% the S&P500.

Analysts await Ocular Therapeutix, Inc. (NASDAQ:OCUL) to report earnings on November, 6. They expect $-0.34 earnings per share, up 37.04 % or $0.20 from last year’s $-0.54 per share. After $-0.37 actual earnings per share reported by Ocular Therapeutix, Inc. for the previous quarter, Wall Street now forecasts -8.11 % EPS growth.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. The company has market cap of $269.76 million. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. It currently has negative earnings. The companyÂ’s lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

More important recent Ocular Therapeutix, Inc. (NASDAQ:OCUL) news were published by: Streetinsider.com which released: “After-Hours Stock Movers 09/06: (OKTA) (FNSR) (FIVE) Higher; (EGAN) (MNLO) (HOME) Lower (more…)” on September 06, 2018, also Nasdaq.com published article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Lindblad Expeditions, Milacron, Lantheus, RCI …”, Streetinsider.com published: “Pre-Open Movers 09/07: (OKTA) (FIVE) (MRVL) Higher; (EGAN) (TSLA) (HOME) Lower (more…)” on September 07, 2018. More interesting news about Ocular Therapeutix, Inc. (NASDAQ:OCUL) was released by: 247Wallst.com and their article: “7 Biotech Stocks Insiders Are Loading Up On” with publication date: August 22, 2018.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.